Cargando…
AB087. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study
BACKGROUND: Although dapoxetine is the only oral pharmacological agent approved for the treatment of premature ejaculation (PE), and is very effective, the discontinuation rate is high. We assessed the discontinuation rate in patients with PE, and the reasons for discontinuation, in real-world pract...
Autores principales: | Park, Nam Cheol, Kim, Tae Nam, Baek, Seung Ryong, Lee, Kyung Min, Choe, Sangmin, Park, Hyun Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186683/ http://dx.doi.org/10.21037/tau.2018.AB087 |
Ejemplares similares
-
Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study
por: Park, Hyun Jun, et al.
Publicado: (2017) -
AB142. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study
por: Park, Hyun Jun, et al.
Publicado: (2015) -
Dapoxetine and premature ejaculation
Publicado: (2023) -
AB218. The size of seminal vesicles on ultrasound is related with premature ejaculation
por: Yao, Bin
Publicado: (2016) -
Dapoxetine and the treatment of premature ejaculation
por: Sangkum, Premsant, et al.
Publicado: (2013)